GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year
The geneType team has achieved clinical proof of concept in key markets including general practice, oncology, and gynecology with repeat sales in each of these markets.
- The geneType team has achieved clinical proof of concept in key markets including general practice, oncology, and gynecology with repeat sales in each of these markets.
- Clinicians embracing and offering geneType to patients have tended to be:
Focussed on offering patients the best available care; and
Comfortable with explaining results to patients. - Clinical adoption of geneType is now in more than 12 US States, Canada and nationally in Australia.
- “Our success in expanding clinician adoption and growth in sales reflects the growing recognition of the transformative potential of personalized medicine,” remarked Simon Morriss, CEO of GENE.